Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Urology
- The association between lower urinary tract symptoms and erectile dysfunction in four centres: the UrEpik study.BJU Int. 2003; 92: 719-725
- Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study.Eur Urol. 2006; 50: 1306-1314
- BPH: epidemiology and comorbidities.Am J Manag Care. 2006; 12: S122-S128
- Incidence and prevalence of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in primary care–the Triumph project.Eur Urol. 2002; 42: 323-328
- Risk factors and comorbid conditions associated with lower urinary tract symptoms: EpiLUTS.BJU Int. 2009; 103: 24-32
- Implications of recent epidemiology studies for the clinical management of lower urinary tract symptoms.BJU Int. 2009; 103: 48-57
- Association of lower urinary tract symptoms and the metabolic syndrome: results from the Boston Area Community Health Survey.J Urol. 2009; 182: 616-624
- Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7).Eur Urol. 2003; 44: 637-649
- Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial.Eur Urol. 2012; 61: 917-925
- Efficacy and safety of tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double-blind, placebo-controlled trial.Eur Urol. 2011; 60: 1105-1113
- Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study.J Urol. 2008; 180: 1228-1234
- Tadalafil 2.5 or 5 mg administered once daily for 12 weeks in men with both erectile dysfunction and signs and symptoms of benign prostatic hyperplasia: results of a randomized, placebo-controlled, double-blind study.J Sex Med. 2012; 9: 271-281
- The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association.J Urol. 1992; 148: 1549-1557
- Measuring disease-specific health status in men with benign prostatic hyperplasia. Measurement Committee of the American Urological Association.Med Care. 1995; 33: AS145-AS155
- The utility of serum prostatic-specific antigen in the management of men with benign prostatic hyperplasia.Int J Impot Res. 2008; 20: S19-S26
- Chronic PDE-5 inhibition in patients with erectile dysfunction - a treatment approach using tadalafil once-daily.Expert Opin Pharmacother. 2012; 13: 1481-1494
- Effects of tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia and on erectile dysfunction in sexually active men with both conditions: analyses of pooled data from 4 randomized, placebo-controlled tadalafil clinical studies.J Sex Med. 2013; (Accepted)
Financial Disclosure: The authors declare that they have no relevant financial interests.
Funding Support: The studies and analyses presented herein were sponsored by Eli Lilly and Company; editorial/medical writing support was provided by Thomas Melby of inVentiv Health Clinical and funded by Eli Lilly and Company.
ScienceDirectAccess this article on ScienceDirect
- ErratumUrologyVol. 83Issue 3
- PreviewThe authors of “Efficacy and Safety of Tadalafil 5 mg Once Daily for Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia: Subgroup Analyses of Pooled Data From 4 Multinational, Randomized, Placebo-controlled Clinical Studies” by Porst H., Oelke M., Goldfischer E.R., Cox D., Watts S., Dey D., et al (Urology 2013;82:667-673) have identified errors mainly related to incorrect cutoff values for predicted prostate volume as outlined below. These errors do not change the interpretation of the data.